ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting
Oric Pharmaceuticals, Inc. (ORIC)
Company Research
Source: GlobeNewswire
Orally bioavailable small molecule CD73 inhibitors reverse immunosuppression by blocking adenosine production Internal research program led to discovery of clinical candidate ORIC-533, which in preclinical studies demonstrated significant anti-tumor single agent efficacy SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today presented research that led to the discovery of potent and orally bioavailable small molecule inhibitors of CD73 at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I. The preclinical data on ORIC’s CD73 program were presented in the “Advances in Cancer Drug Design and Discovery” session in an oral presentation titled “Orally Available Small Molecule CD73 Inhibitor Reverses Immunosuppression Through Blocking of Adenosine Production” (Abstract #1242,
Show less
Read more
Impact Snapshot
Event Time:
ORIC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORIC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORIC alerts
High impacting Oric Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ORIC
News
- ORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.MarketBeat
- ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational UpdatesGlobeNewswire
- ORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
ORIC
Earnings
- 11/12/24 - Miss
ORIC
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- ORIC's page on the SEC website